Sunesis Pharmaceuticals Inc., of South San Francisco, said the first subject was dosed in a phase Ia, randomized, double-blind, placebo-controlled, dose-ranging study to test the safety, pharmacokinetics and pharmacodynamics of its oral, next-generation, noncovalently binding BTK inhibitor, SNS-062, in healthy subjects. Pending successful results from that trial, which is being conducted in Belgium, the company plans to move into phase Ib/II testing in patients with B-cell malignancies later this year.